SEC Tracker
Get the app

Omeros OMER

Omeros FY 2022: net income $47.4M, down 76%; diluted EPS $0.76

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Omeros reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income$47.4M−76% from $194.2M in FY 202110-K income statement, on EDGAR
  2. Diluted EPS$0.76−76% from $3.12 in FY 202110-K income statement, on EDGAR
  3. Cash and cash equivalents$11.0M−89% from $100.8M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$86.5MAgainst −$109.7M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Omeros files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
  2. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  3. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  4. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025
  5. Lineage Cell Therapeutics LCTX public float $162M, Jun 30, 2025